Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Farletuzumab plus carboplatin-based chemotherapy in platinum-sensitive relapsed ovarian cancer with low CA125
jRCT2080222705Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Dec 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in high-grade serous carcinoma (HGSC) and Fallopian tube high-grade serous carcinoma (HGSC) comparing Farletuzumab + carboplatin-based chemotherapy with Placebo + carboplatin-based chemotherapy (2 arms). Primary endpoint: Progression-free survival (PFS). Started Dec 2014; status: completed.
02
Drugs
farletuzumab
03
Conditions
high-grade serous carcinoma (HGSC)Fallopian tube high-grade serous carcinoma (HGSC)
Beyond the preview
Go deeper on jRCT2080222705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222705.